CDX2, a Highly Sensitive and Specific Marker of Adenocarcinomas of Intestinal Origin: An Immunohistochemical Survey of 476 Primary and Metastatic Carcinomas

By R. Werling, H. Yaziji, C. Bacchi, A. Gown. American Journal of Surgical Pathology, 2003

706 citations recorded by the source corpus.

Subfields: Genetics, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/85aa60cd18cfaff3a30d06ccfd764a59419749cd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Jérôme Galon
2. Bernhard Mlecnik
3. Franck Pagès
4. H. Angell
5. Gabriela Bindea
6. F. Marincola
7. A. Berger
8. I. Zlobec

Citations in the corpus

• Colorectal carcinoma: Pathologic aspects. (2012, background): “CDX2 is a marker of enteric differentiation and is positive in >90% of colorectal adenocarcinomas (20,21).”
• Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours (2013, result): “Numerous data collected from large cohorts of human CRCs (with sample sizes n = 415, 599 and 602, respectively) demonstrated that the number, type and location of tumour immune infiltrates in primary tumours are prognostic for disease-free survival (DFS) and overall survival (OS) [9,10,30].”